Targets › IL10
3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology, Immunology; next expected readout Dec 2026.
Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3. (UniProt, P22301)
Open in Phaseline: the race on IL10, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | anti-CD19 IL10/IL15 CAR-NK anti-CD19 chimeric antigen receptor NK cells engineered to co-express IL-10 and IL-15 | CD19, IL10, IL15 | Phase 1 | B-cell Non Hodgkin Lymphoma | Dec 2026 |
| L & L Bio Co., Ltd., Ningbo, China | LB4330 anti-claudin18.2/IL-10 fusion protein | CLDN18, IL10 | Phase 1 | Solid Tumor | Dec 2026 |
| Philogen | F8IL10 Engineered human interleukin-10 fused to F8 antibody fragment targeting fibronectin | IL10 | Phase 1 | Rheumatoid Arthritis (RA) | Sep 2028 |
B-cell Non Hodgkin Lymphoma (1) Rheumatoid Arthritis (RA) (1) Solid Tumor (1)
small molecule (2), protein or peptide (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Philogen (1) L & L Bio Co., Ltd., Ningbo, China (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.